Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03554434 No longer available - Breast Cancer Clinical Trials

An Expanded Access Program for AM0010 (Pegilodecakin)

Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

NCT ID: NCT03005262 No longer available - Prostate Cancer Clinical Trials

MLN8237 for a Subject With Adenocarcinoma of the Prostate

Start date: n/a
Phase:
Study type: Expanded Access

To allow a patient continued access to MLN8237

NCT ID: NCT02826395 No longer available - Prostate Cancer Clinical Trials

C11 Sodium Acetate PET/CT Imaging of PCa

Start date: n/a
Phase:
Study type: Expanded Access

The investigators propose to conduct Carbon-11 Sodium Acetate PET/CT studies. The purpose of our study is to evaluate the impact of Carbon-11 Sodium Acetate PET/CT studies on patient management in patients with prostate cancer.

NCT ID: NCT02531672 No longer available - Prostate Cancer Clinical Trials

Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

NCT ID: NCT01777061 No longer available - Prostate Cancer Clinical Trials

Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan

Start date: n/a
Phase:
Study type: Expanded Access

When evaluating prostate cancer patients for recurrent disease, computed tomography (CT), and magnetic resonance imaging (MRI) are both highly sensitive methods for detecting lymph nodes, but are not specific as to whether the lymph nodes are malignant or benign. While positron emission tomography (PET) utilizing radioactive glucose (FDG) has revolutionized staging, restaging, and monitoring response to therapy in many prevalent cancers such as breast, colorectal, esophageal, head and neck, lung, lymphoma, and melanoma, findings with prostate cancer have proven less sensitive because prostate cancer has a lower avidity for glucose. A newer PET isotope, utilizing acetate that is incorporated into the cell membrane of rapidly proliferating cells, has shown greater sensitivity than FDG in detecting prostate cancer. This study will assess the clinical effectiveness of utilizing [11C]Acetate PET scans in identifying recurrent prostate cancer.